Abbreviated Novartis CTRD Results Template

Sponsor Novartis
Generic Drug Name Aliskiren
Therapeutic Area of Trial Diabetic Macular Edema
Approved Indication Diabetic Macular Edema: Investigational
Protocol Number CSPP100A2244
Title A Randomized, Double-masked, Placebo-controlled, add-on Study to Assess the Efficacy of Oral Aliskiren 300 mg Once Daily for Diabetic Macular Edema
Phase of Development Phase II
Study Start/End Dates 24 September 2008 to 03 February 2011 The current study was discontinued before completing the full enrollment because of recruitment difficulties and new treatment (Lucentis®) has demonstrated significant efficacy in the treatment of DME
Study Design/Methodology The current study was a multi-country, multi-center, randomized, double-masked, placebo-controlled, aliskiren add-on study, which included a 3-month general screening period, a Baseline/Day 1 visit, and a 12 week treatment phase with interim visits on Day 10 (±4 days) and Day 42 (±4 days), and an end of study visit on Day 84 (±4 days). Eligible patients were randomized to receive aliskiren 300 mg orally daily or matching placebo orally daily.

Centres

11 centers in 2 countries: (1) Denmark, (10) United States of America.

Publication

None

Test Product (s), Dose(s), and Mode(s) of Administration

Oral tablets of Aliskiren 300 mg once daily

Statistical Methods

Descriptive statistics (n, mean, standard deviation, median and ranges for continuous variables, frequencies and percentages for categorical variables) had been generated and results were presented by treatment arm and/or visit and, where applicable, by eye (study and fellow). The two treatments were compared using analysis of covariance (change from baseline in central retinal thickness (CRT) & BCVA) and Fisher's Exact Test (responders). All data were listed by patient, treatment arm and, where applicable, by eye (study and fellow).

Study Population: Inclusion/Exclusion Criteria

Inclusion criteria:

- Male and Female patients 18 Years to 85 Years
- Type 1 or type 2 diabetes
- Diabetic macular edema

Exclusion criteria:

- Recent intra-ocular surgery in the study eye (e.g., cataract surgery in the last 6 months)
- Recent laser photocoagulation in the study eye
- Recent treatment with Avastin, Lucentis, or intravitreal corticosteroids in the study eye

Other protocol defined inclusion/exclusion criteria applied.

Participant Flow

	Aliskiren 300 mg (n=20)	Placebo qd (n=19)	Total (n=39)
Patients			
Completed	16 (80.0%)	16 (84.2%)	32 (82.1%)
Discontinued	4 (20.0%)	3 (15.8%)	7 (17.9%)
Main cause of discontinuation			
Adverse event	3	2	5
Abnormal laboratory value	1	1	2

Baseline Characteristics

		Aliskiren 300 mg (n=20)	Placebo (n=19)	Total (n=39)
Age (years)	Mean	64.3	60.1	62.2
	SD	10.76	10.57	10.74
	Median	67.0	60.0	64.0
	Range	38-80	38-82	38-82
Age group – n (%)	18–64 years	9 (45.0%)	13 (68.4%)	22 (56.4%)
	65–84 years	11 (55.0%)	6 (31.6%)	17 (43.6%)
	≥ 85 years	0	0	0
Gender – n (%)	Male	13 (65.0%)	15 (78.9%)	28 (71.8%)
	Female	7 (35.0%)	4 (21.1%)	11 (28.2%)
Race – n (%)	Caucasian	17 (85.0%)	18 (9 .7%)	35 (89.7%)
	Black	2 (10.0%)	0	2 (5.1%)
	Asian	0	1 (5.3%)	1 (2.6%)
	Other	1 (5.0%)	0	1 (2.6)
BMI (kg/m^2)	Mean	29.602	29.768	29.683
	SD	3.7168	4.6199	4.1261
	Median	29.215	29.425	29.425
	Range	21.97-36.43	20.32-39.09	20.32-39.09

Safety Results

Adverse Events by System Organ Class

Frequency Threshold Above Which Other Adverse Events are Reported: 5%

	Aliskiren 300mg	**Placebo**
Total # participants affected/at risk	**13/20 (65%)**	**9/19 (47.37%)**
Cardiac disorders		
Atrial fibrillation † A		
# participants affected/at risk	0/20 (0%)	1/19 (5.26%)
Palpitations † A		
# participants affected/at risk	0/20 (0%)	1/19 (5.26%)
Eye disorders		
Cataract subcapsular † A		
# participants affected/at risk	0/20 (0%)	1/19 (5.26%)
Choroidal neovascularisation † A		
# participants affected/at risk	1/20 (5%)	0/19 (0%)
Foreign body sensation in eyes † A		
# participants affected/at risk	1/20 (5%)	0/19 (0%)
Hyalosis asteroid † A		
# participants affected/at risk	1/20 (5%)	0/19 (0%)
Macular oedema † A		
# participants affected/at risk	1/20 (5%)	1/19 (5.26%)
Retinal exudates † A		
# participants affected/at risk	0/20 (0%)	1/19 (5.26%)
Retinal neovascularisation † A		
# participants affected/at risk	1/20 (5%)	0/19 (0%)
Vision blurred † A		

# participants affected/at risk	1/20 (5%)	0/19 (0%)
Vitreous detachment † A		
# participants affected/at risk	1/20 (5%)	0/19 (0%)
Gastrointestinal disorders		
Abdominal pain upper † A		
# participants affected/at risk	0/20 (0%)	1/19 (5.26%)
Diarrhoea † A		
# participants affected/at risk	1/20 (5%)	0/19 (0%)
Flatulence † A		
# participants affected/at risk	1/20 (5%)	0/19 (0%)
Oesophagitis † A		
# participants affected/at risk	0/20 (0%)	1/19 (5.26%)
Vomiting † A		
# participants affected/at risk	0/20 (0%)	2/19 (10.53%)
General disorders		
Fatigue † A		
# participants affected/at risk	1/20 (5%)	0/19 (0%)
Pyrexia † A		
# participants affected/at risk	0/20 (0%)	1/19 (5.26%)
Immune system disorders		
Seasonal allergy † A		
# participants affected/at risk	1/20 (5%)	1/19 (5.26%)
Infections and infestations		
Folliculitis † A		
# participants affected/at risk	0/20 (0%)	1/19 (5.26%)
Fungal skin infection † A		
# participants affected/at risk	1/20 (5%)	0/19 (0%)

Gastroenteritis viral † A		
# participants affected/at risk	1/20 (5%)	1/19 (5.26%)
Respiratory tract infection † A		
# participants affected/at risk	1/20 (5%)	0/19 (0%)
Sinusitis † A		
# participants affected/at risk	1/20 (5%)	0/19 (0%)
Urinary tract infection † A		
# participants affected/at risk	1/20 (5%)	1/19 (5.26%)
Injury, poisoning and procedural complications		
Tooth fracture † A		
# participants affected/at risk	1/20 (5%)	0/19 (0%)
Investigations		
Blood pressure increased † A		
# participants affected/at risk	0/20 (0%)	1/19 (5.26%)
Weight decreased † A		
# participants affected/at risk	0/20 (0%)	1/19 (5.26%)
Metabolism and nutrition disorders		
Decreased appetite † A		
# participants affected/at risk	0/20 (0%)	1/19 (5.26%)
Diabetes mellitus † A		
# participants affected/at risk	0/20 (0%)	1/19 (5.26%)
Hypoglycaemia † A		
# participants affected/at risk	1/20 (5%)	0/19 (0%)
Musculoskeletal and connective tissue disorders		
Arthritis † A		
# participants affected/at risk	1/20 (5%)	0/19 (0%)
Muscle spasms † A		
# participants affected/at risk	1/20 (5%)	0/19 (0%)

Myalgia † A		
# participants affected/at risk	1/20 (5%)	0/19 (0%)
Pain in extremity † A		
# participants affected/at risk	1/20 (5%)	0/19 (0%)
Pain in jaw † A		
# participants affected/at risk	1/20 (5%)	0/19 (0%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		
Basal cell carcinoma † A		
# participants affected/at risk	2/20 (10%)	0/19 (0%)
Nervous system disorders		
Diabetic neuropathy † A		
# participants affected/at risk	0/20 (0%)	1/19 (5.26%)
Dizziness † A		
# participants affected/at risk	2/20 (10%)	2/19 (10.53%)
Headache † A		
# participants affected/at risk	2/20 (10%)	2/19 (10.53%)
Paraesthesia † A		
# participants affected/at risk	1/20 (5%)	0/19 (0%)
Sinus headache † A		
# participants affected/at risk	0/20 (0%)	1/19 (5.26%)
Respiratory, thoracic and mediastinal disorders		
Cough † A		
# participants affected/at risk	0/20 (0%)	1/19 (5.26%)
Epistaxis † A		
# participants affected/at risk	1/20 (5%)	0/19 (0%)
Oropharyngeal pain † A		

# participants affected/at risk	0/20 (0%)	1/19 (5.26%)
Sinus congestion † A		
# participants affected/at risk	0/20 (0%)	1/19 (5.26%)
Skin and subcutaneous tissue disorders		
Dry skin † A		
# participants affected/at risk	0/20 (0%)	1/19 (5.26%)
Vascular disorders		
Hypertension † A		
# participants affected/at risk	0/20 (0%)	1/19 (5.26%)
Hypotension † A		
# participants affected/at risk	2/20 (10%)	0/19 (0%)

Number of patients who experienced serious or clinically significant adverse events (safety set)

	Aliskiren 300 mg	Placebo
	N=20	N=19
Patients with serious or significant AEs	**n**	**n**
SAEs	2	2
Discontinued due to AEs	3	2
Discontinued due to SAEs	0	2

Serious Adverse Events

	Aliskiren 300mg	Placebo
Total # participants affected/at risk	**2/20 (10%)**	**2/19 (10.53%)**
Infections and infestations		
Cellulitis † A		
# participants affected/at risk	1/20 (5%)	0/19 (0%)
Pneumonia † A		
# participants affected/at risk	1/20 (5%)	0/19 (0%)
Pneumonia legionella † A		
# participants affected/at risk	0/20 (0%)	1/19 (5.26%)
Metabolism and nutrition disorders		
Diabetic foot † A		
# participants affected/at risk	1/20 (5%)	0/19 (0%)
Nervous system disorders		
Cerebrovascular accident † A		
# participants affected/at risk	0/20 (0%)	1/19 (5.26%)

Date of Clinical Trial Report 03 January 2012
Date Inclusion on Novartis Clinical Trial Results Database 03 February 2012
Date of Latest Update